author-photo

Bernard Escudier

Institut Gustave Roussy

739

Papers

46121

Citations

Citation Trend

Filter By

Papers (739) Sort By

JournalConferenceOthers

349 Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
TIVO-3: Age-related tolerability outcomes of tivozanib versus sorafenib in metastatic relapsed or refractory renal cell carcinoma, a subgroup analysis of the TIVO-3 clinical trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Impact of nephrectomy on clinical outcomes and feasibility of radiation therapy in patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with nivolumab: Subgroup analyses from the WITNESS real-world study in France

2021
Show All
- Source
- Cite
- Save
Citations (0)
TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
ACTIVITY OF SYSTEMIC TREATMENTS AFTER CABOZANTINIB FAILURE IN ADVANCED METASTATIC RENAL CELL CARCINOMA

2021 Clinical Genitourinary Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC)

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
IO-Synthesise RCC: Real-world outcomes with nivolumab in previously treated advanced renal cell carcinoma, a pooled analysis of patients from France and Germany

2021
Show All
- Source
- Cite
- Save
Citations (0)
Checkpoints inhibitors in Metastatic Papillary Renal Cell Carcinoma

2021 Cancer Treatment Reviews
Show All
- Source
- Cite
- Save
Citations (1)
Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号